Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VIUMF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
M-9140
|
|||||
| Synonyms |
M 9140; M-9140; M9140
Click to Show/Hide
|
|||||
| Organization |
Merck KGaA; EMD Serono Research & Development Institute, Inc.
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 5 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-glucuronide-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
